Monoclonal antibodies (mAbs) are currently the most investigated therapeutic 
compounds in oncology, but there is no monoclonal antibody approved in the 
treatment of multiple myeloma (MM). Nevertheless several really promising 
molecules are under investigation in phase III clinical trials. Dominantly 
daratumumab (anti-CD38) and elotuzumab (anti-CS1) showed extraordinary 
effectiveness in phase I/II trials. The toxicity was acceptable which is 
important for their addition to standard anti-myeloma agents like proteasome 
inhibitors or immunomodulatory drugs. Monoclonal antibodies such as denosumab 
(anti-RANKL) or BHQ880 (anti-DKK-1) are investigated also in the management of 
myeloma bone disease. This review is focused on the most promising mAbs, their 
mechanisms of action and the rationale of use. Practically all available results 
have been described. If the ongoing trials confirm the efficacy and safety of 
mAbs, they would become an important part of MM treatment that would be 
translated in the further improvement of therapeutic outcomes.